About Us

Management

Anand Kumble
Chief Executive Officer

Howard Moore graduated from Massey University with a Bachelor of Food Technology. His early career was in the New Zealand dairy industry with NZ Co-op Dairy Co, Alfa Laval, NZ Dairy Board and Kiwi Dairies. He was a driving force in the New Zealand dairy industry committing to invest $150 million in an ag-biotechnology start-up company; ViaLactia. Howard and the late Professor Ross Clark were co-founders of Tercica, an Auckland start-up company which relocated to the USA, in-licensed and then had IGF-1 approved as a drug and achieved a listing for Tercica on NASDAQ. Howard then returned to New Zealand and became Executive Director for Direct Capital’s $100 million life sciences fund, BioPacificVentures. Howard has also has spent 6 years working in the dairy industry in China. His career has been hallmarked by fund raising, commercialising technology, developing early stage companies, and sales and marketing.

h.moore@pictordx.com
Anand Kumble
Managing Director, Pictor Diagnostics India

Mr. Amit Somani, BE, EPMB is the Managing Director of Pictor Diagnostics India. Following his education in Engineering from Pune University, Amit started a blood banking software business and went on to receive his EPMB from the Indian Institute of Management in Calcutta. He then worked at global consulting companies, followed by a senior managerial role at Reliance Jio. Most recently he was head of customer experience management at Flipkart before joining Pictor Diagnostics India.

a.somani@pictordx.com

Board

Anand Kumble
Acting Chair

Maxine Simmons founded one of New Zealand’s first biotechnology companies and has since held many influential roles in science commercialisation and early stage biotechnology company development. These include being a founding director of Industry New Zealand (now New Zealand Trade and Enterprise); a director of the Foundation for Research, Science and Technology; Chair of NZBIO; a New Zealand representative on ABAC (the APEC Business Advisory Council).

Maxine is currently Executive Director of Cure Kids Ventures, a seed and early stage company investment fund that invests in the commercialisation of healthcare innovations with a potential to benefit child health.

Maxine holds a Master of Science degree in biological sciences from the University of Auckland, is a chartered member of the NZ Institute of Directors and holds a number of private company directorships.

Maxine was recently appointed a Companion of the New Zealand Order of Merit for her services to science, particularly biotechnology.

Anand Kumble

Dr. Lee Mathias, DHSc is a director of Pictor. Lee has many years of experience as a director in public health services including Crown Health Enterprises and Hospital and Health Services, ACC, social enterprises (NGOs) and private companies.

Lee’s entrepreneurial activity includes start-up companies Birthcare Auckland Limited, the first private maternity company to contract with the public sector in NZ and Labtests Auckland Limited which won the public contract to provide community laboratory services for the people of Auckland.

Prior to that Lee was the General Manager for Strategic Planning with Auckland Healthcare Services (A+), Manager for Clinical Support Services for South Auckland and Principal Nurse at Middlemore Hospital. Lee maintains a portfolio of lectureships with AUT, University of the South Pacific and Auckland University.

Lee Mathias is a registered nurse and holds a BA from Massey University, an MBA from Auckland University and DHSc from AUT University, Auckland, New Zealand. She is an accredited fellow of the Institute of Directors in New Zealand and an Ass. Fellow of the New Zealand Institute of Healthcare Managers.

Anand Kumble

Paul Kinnon has held leadership positions with Transgenomic Inc., Arch Global Research, ZyGEM Corp., Thermo Fisher (Life Technologies), Guava Technologies and Cellomics. As President and CEO at Transgenomic, he was responsible for restructuring the Company via M&A activity; divesting two major business units and two product lines generating ~$10 million in non-dilutive funding while significantly reducing losses; maintaining NASDAQ status for over three years; while restructuring the company, and strategically changing its direction. He has a proven track record for transforming organizations large and small while driving commercial success and growth; broad experience in leadership, capital fundraising, M&A business development, commercial organizations, technology and product development in multiple sectors (oncology, discovery, clinical diagnostics, clinical development and platform development); as well as developing and implementing novel and successful commercial launches, with strong mentoring and exceptional organization/leadership skills and global industrywide network of personal and business contacts.